株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

Ossotideの中国市場の分析

Investigation Report on Chinese Ossotide Market, 2018-2022

発行 China Research and Intelligence 商品コード 674759
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.53円で換算しております。
Back to Top
Ossotideの中国市場の分析 Investigation Report on Chinese Ossotide Market, 2018-2022
出版日: 2018年08月01日 ページ情報: 英文 30 Pages
概要

Ossotideは骨細胞を刺激し骨形成を促進するほか、カルシウムおよびリンの代謝を調節することで骨のカルシウム沈着を増大させ、骨粗鬆症を予防する作用があります。中国におけるOssotideの売上は、2007年の1億2,000万中国元から、2017年には3億6,300万中国元へ増加し、今後数年間にかけても市場成長が続くものと予測されています。

当レポートでは、中国のOssotide市場を調査し、製品の概要、中国全体および地域別の売上の推移、製品価格、主要企業の動向分析、市場の見通しなどについてまとめています。

第1章 Ossotideの概要

  • Ossotideの適応症
  • 中国におけるOssotideの開発の沿革
  • 中国におけるOssotideの特許および政府承認

第2章 中国におけるOssotideの売上の推移(実績値)

  • Ossotideの売上額
    • 売上額:全体
    • 売上額:地域別
  • Ossotideの売上量
    • 売上量:全体
    • 売上量:地域別
  • Ossotideの剤型
    • 注射剤
    • 錠剤

第3章 Ossotideの主要メーカー

  • 主要メーカーの市場シェア
    • 市場シェア:金額ベース
    • 市場シェア:重量ベース
  • Harbin Medisan Pharmaceutical Co., Ltd.
  • Heilongjiang ZBD Pharmaceutical Co., Ltd.
  • Heilongjiang Jiangshi Pharmaceutical Co., Ltd.
  • Nanjing Xinbai Pharmaceutical Co., Ltd.
  • Anhui Hongye Pharmaceutical Co., Ltd.

第4章 Ossotideの価格

  • Harbin Medisan Pharmaceutical Co., Ltd. (Maijinli)
  • Heilongjiang ZBD Pharmaceutical Co., Ltd.
  • Heilongjiang Jiangshi Pharmaceutical Co., Ltd. (Gujie)
  • Nanjing Xinbai Pharmaceutical Co., Ltd. (Guzheng)
  • Anhui Hongye Pharmaceutical Co., Ltd. (Shundaxin)

第5章 中国のOssotide市場の見通し

  • Ossotide開発への影響要因
  • 市場規模の予測
  • 市場動向の予測

図表リスト

目次
Product Code: 1808322

Description

According to statistics, the incidence of rheumatoid arthritis in China is 0.2% to 0.36%, and the number of patients is up to 5 to 10 million. Like rheumatoid arthritis, osteoarthritis is one of the most common arthritis and a manifestation of articular degeneration with age. At the end of 2017, the number of people aged 60 and above reached 241 million in China, accounting for 17.3% of the total population. Some research has pointed out that over 60% of Chinese people aged 60 and above are suffering from osteoarthritis as the population is ageing. Typical symptoms of osteoarthritis are joint pains, joint deformities, and joint dysfunction, decreasing patients' mobility and quality of life.

Ossotide can regulate bone metabolism and stimulate the proliferation of bone cells to foster the formation of new bones. It can also regulate calcium and phosphorus metabolism and increase bone calcium deposition to prevent osteoporosis. Ossotide was originally developed by Nanjing Xinbai Pharmaceutical Co., Ltd. There are many Ossotide manufacturers in China. The top 5 market players are Harbin Medisan Pharmaceutical Co., Ltd., Heilongjiang ZBD Pharmaceutical Co., Ltd., Heilongjiang Jiangshi Pharmaceutical Co., Ltd., Nanjing Xinbai Pharmaceutical Co., Ltd. and Anhui Hongye Pharmaceutical Co., Ltd. In 2017, their market share by sales revenue reached over 90%. Harbin Medisan Pharmaceutical Co., Ltd. captured the biggest market share by sales value about 35%.

According to CRI, after Ossotide was launched in China, the sales value of Ossotide kept growing before 2012 and fluctuated from 2013 to 2017. Overall, the annual sales value in China increased from less than CNY 120 million in 2007 to CNY 363 million in 2017. The Chinese Ossotide market will continue to grow in the coming years.

Topics Covered:

  • Development environment of Ossotide
  • Sales of Ossotide in China
  • Competition pattern of Chinese Ossotide Market
  • Major Ossotide manufacturers in China
  • Prices of Ossotide in China
  • Prospect of the Chinese Ossotide market from 2018 to 2022

Table of Contents

1 Relevant Concepts of Ossotide

  • 1.1 Indications for Ossotide
  • 1.2 Development History of Ossotide in China
  • 1.3 Patents and Government Approval on Ossotide in China

2 Sales of Ossotide in China, 2013-2017

  • 2.1 Sales Value of Ossotide
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Ossotide
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Ossotide by Dosage Form in China, 2013-2017
    • 2.3.1 Injections
    • 2.3.2 Tablets

3 Major Ossotide Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Ossotide Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Harbin Medisan Pharmaceutical Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales
  • 3.3 Heilongjiang ZBD Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales
  • 3.4 Heilongjiang Jiangshi Pharmaceutical Co., Ltd.
  • 3.5 Nanjing Xinbai Pharmaceutical Co., Ltd.
  • 3.6 Anhui Hongye Pharmaceutical Co., Ltd.

4 Prices of Different Manufacturers' Ossotide in China, 2017-2018

  • 4.1 Harbin Medisan Pharmaceutical Co., Ltd. (Maijinli)
  • 4.2 Heilongjiang ZBD Pharmaceutical Co., Ltd.
  • 4.3 Heilongjiang Jiangshi Pharmaceutical Co., Ltd. (Gujie)
  • 4.4 Nanjing Xinbai Pharmaceutical Co., Ltd. (Guzheng)
  • 4.5 Anhui Hongye Pharmaceutical Co., Ltd. (Shundaxin)

5 Prospect of Chinese Ossotide Market, 2018-2022

  • 5.1 Analysis on Factors Influencing Development of Ossotide in China
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Governmental Approval of Ossotide in China
  • Chart Sales Value of Ossotide in China, 2013-2017
  • Chart Sales Value of Ossotide in Parts of China, 2013-2017
  • Chart Sales Volume of Ossotide in China, 2013-2017
  • Chart Market Share of Top 5 Ossotide Manufacturers by Sales Value, 2013-2017
  • Chart Sales Value and Market Share of Harbin Medisan Pharmaceutical Co., Ltd.'s Ossotide in China, 2013-2017
  • Chart Sales Value and Market Share of Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Ossotide in China, 2013-2017
  • Chart Sales Value and Market Share of Heilongjiang Jiangshi Pharmaceutical Co., Ltd.'s Ossotide in China, 2013-2017
  • Chart Sales Value and Market Share of Ossotide Injections in China, 2013-2017
  • Chart Sales Value and Market Share of Ossotide Tablets in China, 2013-2017
  • Chart Prices of Nanjing Xinbai Pharmaceutical Co., Ltd.'s Ossotide in Parts of China, 2017-2018
  • Chart Prices of Harbin Medisan Pharmaceutical Co., Ltd.'s Ossotide in Parts of China, 2017-2018
  • Chart Prices of Heilongjiang Jiangshi Pharmaceutical Co., Ltd.'s Ossotide in Parts of China, 2014
Back to Top